Outcome Capital Taps Veteran Banker Jaison Ellis in Strategic M&A Push

BOSTON, MA – April 23, 2026 – Outcome Capital, a specialized life sciences and healthcare advisory firm, has bolstered its senior leadership by appointing veteran investment banker Jaison Ellis as a Managing Director. The move signals a significant strategic push to deepen its transactional expertise and expand its footprint amidst a fiercely competitive and rapidly evolving healthcare M&A landscape.

Mr. Ellis, who will be based in Charlotte, North Carolina, brings a formidable track record from his tenure at major financial institutions, including Wells Fargo, BMO Capital Markets, and Credit Suisse. His appointment is a key part of Outcome Capital's deliberate expansion, which focuses on integrating deep sector knowledge with high-level transactional execution to guide innovative companies through critical growth phases.

A Strategic Hire in a Competitive Market

Outcome Capital’s decision to bring on a banker of Ellis’s caliber underscores the intense competition among advisory firms to secure top talent. The life sciences investment banking sector, populated by specialized powerhouses like Leerink Partners and the large healthcare divisions of global banks, demands a sophisticated blend of scientific and financial acumen. For boutique firms like Outcome Capital, senior hires with extensive deal-making experience are a primary currency for differentiation and growth.

The firm has consistently emphasized its “strategy-led execution” model, which combines a multidisciplinary team of former CEOs, scientists, and clinicians with seasoned financial experts. The addition of Ellis reinforces this platform, adding significant weight to its transactional capabilities. Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital, highlighted this strategy in the announcement.

“We continue to expand our specialized, strategy-led execution model, enabling us to deliver premium outcomes for our clients as they navigate critical inflection points,” Dr. Ben-Joseph commented. “Central to this effort is our unwavering focus on attracting and retaining top talent that consistently delivers superior value to our clients. Jaison’s diverse skill set and deep transaction experience make him an outstanding addition to our platform and will support our continued growth while reinforcing our core value proposition of combining sector expertise with transaction excellence.”

This focus on talent is crucial in a market poised for a rebound. After a slower period, analysts anticipate a recovery in healthcare M&A, driven by large biopharma companies seeking to replenish pipelines and smaller innovators needing capital and strategic partnerships. Firms with the expertise to navigate these complex deals will be best positioned to succeed.

The Veteran Dealmaker's Profile

Jaison Ellis is not just another hire; he is a seasoned professional credited with originating and executing over $150 billion in M&A and capital raising transactions. His expertise spans some of the most active subsectors in healthcare, including biopharmaceuticals, pharma services, and laboratory services—all areas experiencing significant investment and consolidation.

Prior to joining Outcome Capital, Ellis served as a Managing Director in the Healthcare Investment Banking group at Wells Fargo, a position he held since 2013. His career also includes pivotal roles in the Mergers and Acquisitions group at BMO Capital Markets and within the Alternative Investments and Financial Sponsors groups at Credit Suisse in New York. This background provides him with a deep network and a comprehensive understanding of the capital markets, from venture-backed startups to publicly traded giants.

His reputation as a trusted advisor to management teams and boards on complex strategic transactions, including sales, divestitures, and recapitalizations, aligns perfectly with Outcome Capital’s advisory-centric approach. In a statement, Ellis expressed his enthusiasm for the new role.

“I’m delighted to join such a distinguished and high-quality team of professionals and excited to further Outcome’s vital work of helping clients achieve their strategic goals amidst a rapidly evolving healthcare landscape with vast opportunities for value creation,” said Ellis. Graduating summa cum laude from Morehouse College, his career reflects a consistent trajectory of excellence in the high-stakes world of finance.

Beyond Boston: The Significance of a Charlotte Base

While Outcome Capital is headquartered in the life sciences hub of Boston, the decision to base Mr. Ellis in Charlotte, North Carolina, is a noteworthy strategic signal. Far from being a simple matter of accommodating a new hire's location, it represents a calculated expansion into one of the nation's fastest-growing financial and life sciences corridors.

Charlotte has firmly established itself as the second-largest banking center in the United States, with a rapidly growing employment base in financial services. More importantly, the city and the broader North Carolina region are becoming a formidable force in the life sciences. The state has seen its life sciences industry grow by 30% since 2018, attracting major investments from global companies. The greater Charlotte region alone attracted over $80 million in life sciences investments in 2025, and local leaders are actively fostering this growth, even proclaiming a “Charlotte Life Sciences Week” to celebrate the sector's momentum.

By establishing a senior presence in Charlotte, Outcome Capital gains a valuable foothold in the Southeast. This move allows the firm to tap into a burgeoning ecosystem of biomedical research, clinical innovation, and a growing talent pipeline. It positions the firm closer to an emerging set of clients and deal opportunities outside the traditional, and often saturated, hubs of Boston and San Francisco. This geographic diversification complements the firm's strategic goal of broadening its market reach and providing localized expertise.

Deepening Specialization and Future Synergies

The timing of Ellis's arrival is particularly opportune, aligning seamlessly with Outcome Capital's recent strategic initiatives. In late 2025, the firm launched a dedicated Healthcare Services Practice and a Pharmacy and Related Services Advisory Board to enhance its capabilities in these evolving sectors. Ellis’s deep experience in pharma services and lab services directly supports and strengthens these new focus areas, providing immediate, high-level expertise.

His background in biopharmaceuticals is equally critical. With large pharmaceutical companies facing patent cliffs and pressure for revenue growth, M&A remains a primary tool for acquiring innovation. Ellis's experience in structuring and executing deals in this space will be invaluable as Outcome Capital advises clients on both buy-side and sell-side mandates. His ability to navigate the complex valuation and integration challenges inherent in biopharma transactions will enhance the firm’s ability to deliver on its promise of “premium outcomes.”

This strategic alignment of talent and market opportunity is at the core of Outcome Capital’s model. The firm’s multidisciplinary team of scientists, clinicians, and former industry executives provides the deep technical and operational diligence, while seasoned bankers like Ellis bring the transactional prowess to close deals effectively. This combination is designed to help innovative companies progress from “bench to bedside,” supported by a financial strategy that maximizes value at every stage. With Jaison Ellis on board, Outcome Capital is better equipped than ever to execute this vision.